CYP2E1 has been implicated in the progression of nonalcoholic fatty liver disease (NAFLD) to its more severe form, nonalcoholic steatohepatitis (NASH), which involves inflammation and fibrosis [97]. This evidence concerns the gene CYP2E1 and metabolic dysfunction-associated steatohepatitis.